John Tavis - Publications

Affiliations: 
Saint Louis University, St. Louis, MO, United States 
Area:
Molecular Biology

68 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2023 Jones T, Tavis JE, Li Q, Riabova O, Monakhova N, Bradley DP, Lane TR, Makarov V, Ekins S. Antiviral Evaluation of Dispirotripiperazines against Hepatitis B Virus. Journal of Medicinal Chemistry. PMID 37611244 DOI: 10.1021/acs.jmedchem.3c00974  0.403
2022 Tajwar R, Bradley DP, Ponzar NL, Tavis JE. Predicted structure of the hepatitis B virus polymerase reveals an ancient conserved protein fold. Protein Science : a Publication of the Protein Society. 31: e4421. PMID 36173165 DOI: 10.1002/pro.4421  0.342
2022 Geerling E, Murphy V, Mai MC, Stone ET, Casals AG, Hassert M, O'Dea AT, Cao F, Donlin MJ, Elagawany M, Elgendy B, Pardali V, Giannakopoulou E, Zoidis G, Schiavone DV, ... ... Tavis JE, et al. Metal coordinating inhibitors of Rift Valley fever virus replication. Plos One. 17: e0274266. PMID 36112605 DOI: 10.1371/journal.pone.0274266  0.313
2022 Schiavone DV, Kapkayeva DM, Li Q, Woodson ME, Gazquez Casals A, Morrison LA, Tavis JE, Murelli RP. Synthesis of Polyoxygenated Tropolones and their Antiviral Activity Against Hepatitis B Virus and Herpes Simplex Virus-1. Chemistry (Weinheim An Der Bergstrasse, Germany). PMID 34984767 DOI: 10.1002/chem.202104112  0.315
2021 Clark DN, Tajwar R, Hu J, Tavis JE. The hepatitis B virus polymerase. The Enzymes. 50: 195-226. PMID 34861937 DOI: 10.1016/bs.enz.2021.06.010  0.348
2021 Prifti GM, Moianos D, Giannakopoulou E, Pardali V, Tavis JE, Zoidis G. Recent Advances in Hepatitis B Treatment. Pharmaceuticals (Basel, Switzerland). 14. PMID 34062711 DOI: 10.3390/ph14050417  0.386
2020 Hao S, Ning K, Wang X, Wang J, Cheng F, Ganaie SS, Tavis JE, Qiu J. Establishment of a Replicon Reporter of the Emerging Tick-Borne Bourbon Virus and Use It for Evaluation of Antivirals. Frontiers in Microbiology. 11: 572631. PMID 33013808 DOI: 10.3389/Fmicb.2020.572631  0.347
2020 Bak E, Miller JT, Noronha A, Tavis J, Gallicchio E, Murelli RP, Le Grice SFJ. 3,7-Dihydroxytropolones Inhibit Initiation of Hepatitis B Virus Minus-Strand DNA Synthesis. Molecules (Basel, Switzerland). 25. PMID 32992516 DOI: 10.3390/molecules25194434  0.34
2020 Ren Y, Ma Y, Cherukupalli S, Tavis JE, Menéndez-Arias L, Liu X, Zhan P. Discovery and optimization of benzenesulfonamides-based hepatitis B virus capsid modulators via contemporary medicinal chemistry strategies. European Journal of Medicinal Chemistry. 206: 112714. PMID 32949990 DOI: 10.1016/j.ejmech.2020.112714  0.374
2020 Mosa AI, AbouHaidar MG, Urbanowicz RA, Tavis JE, Ball JK, Feld JJ. Role of HVR1 sequence similarity in the cross-genotypic neutralization of HCV. Virology Journal. 17: 140. PMID 32948191 DOI: 10.1186/s12985-020-01408-9  0.379
2020 Ngwaga T, Kong L, Lin D, Schoborg C, Taylor LE, Mayer KH, Klein RS, Celentano DD, Sobel JD, Jamieson DJ, King CC, Tavis JE, Blackard JT. Diversity of the hepatitis C virus NS5B gene during HIV co-infection. Plos One. 15: e0237162. PMID 32750098 DOI: 10.1371/Journal.Pone.0237162  0.468
2020 Pierra Rouviere C, Dousson CB, Tavis JE. HBV replication inhibitors. Antiviral Research. 179: 104815. PMID 32380149 DOI: 10.1016/j.antiviral.2020.104815  0.379
2019 Edwards TC, Ponzar NL, Tavis JE. Shedding light on RNaseH: a promising target for hepatitis B virus (HBV). Expert Opinion On Therapeutic Targets. PMID 31084514 DOI: 10.1080/14728222.2019.1619697  0.318
2018 Tavis JE, Zoidis G, Meyers MJ, Murelli RP. Chemical Approaches to Inhibiting the Hepatitis B Virus Ribonuclease H. Acs Infectious Diseases. PMID 29565562 DOI: 10.1021/Acsinfecdis.8B00045  0.404
2017 Long KR, Lomonosova E, Li Q, Ponzar NL, Villa JA, Touchette E, Rapp S, Liley RM, Murelli RP, Grigoryan A, Buller RM, Wilson L, Bial J, Sagartz JE, Tavis JE. Efficacy of hepatitis B virus ribonuclease H inhibitors, a new class of replication antagonists, in FRG human liver chimeric mice. Antiviral Research. PMID 29129708 DOI: 10.1016/J.Antiviral.2017.11.008  0.403
2017 Chen Y, Hu J, Cai X, Huang Y, Zhou X, Tu Z, Hu J, Tavis JE, Tang N, Huang A, Hu Y. APOBEC3B edits HBV DNA and inhibits HBV replication during reverse transcription. Antiviral Research. PMID 29129707 DOI: 10.1016/j.antiviral.2017.11.006  0.367
2017 Alter H, Block TM, Brown N, Brownstein A, Brosgart C, Chang KM, Chen PJ, Chisari FV, Cohen C, El-Serag H, Feld J, Gish R, Glenn J, Greten T, Guo H, ... ... Tavis J, et al. A Research Agenda for Curing Chronic Hepatitis B Virus Infection. Hepatology (Baltimore, Md.). PMID 28877549 DOI: 10.1002/Hep.29509  0.431
2017 Lomonosova E, Daw J, Garimallaprabhakaran AK, Agyemang NB, Ashani Y, Murelli RP, Tavis JE. Efficacy and cytotoxicity in cell culture of novel α-hydroxytropolone inhibitors of Hepatitis B virus ribonuclease H. Antiviral Research. PMID 28633989 DOI: 10.1016/J.Antiviral.2017.06.014  0.326
2017 Edwards TC, Lomonosova E, Patel JA, Li Q, Villa JA, Gupta AK, Morrison LA, Bailly F, Cotelle P, Giannakopoulou E, Zoidis G, Tavis JE. Inhibition of hepatitis B virus replication by N-hydroxyisoquinolinediones and related polyoxygenated heterocycles. Antiviral Research. PMID 28450058 DOI: 10.1016/J.Antiviral.2017.04.012  0.325
2017 Lomonosova E, Tavis JE. In Vitro Enzymatic and Cell Culture-Based Assays for Measuring Activity of HBV RNaseH Inhibitors. Methods in Molecular Biology (Clifton, N.J.). 1540: 179-192. PMID 27975316 DOI: 10.1007/978-1-4939-6700-1_14  0.351
2017 Lomonosova E, Zlotnick A, Tavis JE. Synergistic Interactions between Hepatitis B Virus RNase H Antagonists and Other Inhibitors. Antimicrobial Agents and Chemotherapy. 61. PMID 27956427 DOI: 10.1128/Aac.02441-16  0.379
2016 Lu G, Villa JA, Donlin M, Edwards TC, Cheng X, Heier RF, Meyers MJ, Tavis JE. Hepatitis B virus genetic diversity has minimal impact on sensitivity of the viral ribonuclease H to inhibitors. Antiviral Research. PMID 27693161 DOI: 10.1016/j.antiviral.2016.09.009  0.414
2016 Villa JA, Pike DP, Patel KB, Lomonosova E, Lu G, Abdulqader R, Tavis JE. Purification and enzymatic characterization of the hepatitis B virus ribonuclease H, a new target for antiviral inhibitors. Antiviral Research. PMID 27321664 DOI: 10.1016/j.antiviral.2016.06.005  0.345
2015 Tavis JE, Lomonosova E. The hepatitis B virus ribonuclease H as a drug target. Antiviral Research. 118: 132-8. PMID 25862291 DOI: 10.1016/j.antiviral.2015.04.002  0.395
2015 Lu G, Lomonosova E, Cheng X, Moran EA, Meyers MJ, Le Grice SF, Thomas CJ, Jiang JK, Meck C, Hirsch DR, D'Erasmo MP, Suyabatmaz DM, Murelli RP, Tavis JE. Hydroxylated tropolones inhibit hepatitis B virus replication by blocking viral ribonuclease H activity. Antimicrobial Agents and Chemotherapy. 59: 1070-9. PMID 25451058 DOI: 10.1128/Aac.04617-14  0.363
2014 Donlin MJ, Lomonosova E, Kiss A, Cheng X, Cao F, Curto TM, Di Bisceglie A, Tavis JE. HCV genome-wide genetic analyses in context of disease progression and hepatocellular carcinoma. Plos One. 9: e103748. PMID 25079603 DOI: 10.1371/journal.pone.0103748  0.438
2014 Gehring AJ, Bertoletti A, Tavis JE. Host factor-targeted hepatitis B virus therapies Intervirology. 57: 158-162. PMID 25034483 DOI: 10.1159/000360938  0.39
2014 Chowdhury AY, Tavis JE, George SL. Human pegivirus (GB virus C) NS3 protease activity inhibits induction of the type I interferon response and is not inhibited by HCV NS3 protease inhibitors. Virology. 456: 300-9. PMID 24889249 DOI: 10.1016/J.Virol.2014.03.018  0.774
2014 Cai CW, Lomonosova E, Moran EA, Cheng X, Patel KB, Bailly F, Cotelle P, Meyers MJ, Tavis JE. Hepatitis B virus replication is blocked by a 2-hydroxyisoquinoline-1,3(2H,4H)-dione (HID) inhibitor of the viral ribonuclease H activity. Antiviral Research. 108: 48-55. PMID 24858512 DOI: 10.1016/j.antiviral.2014.05.007  0.325
2014 Cao F, Jones S, Li W, Cheng X, Hu Y, Hu J, Tavis JE. Sequences in the terminal protein and reverse transcriptase domains of the hepatitis B virus polymerase contribute to RNA binding and encapsidation. Journal of Viral Hepatitis. 21: 882-93. PMID 24401091 DOI: 10.1111/Jvh.12225  0.398
2014 Jones SA, Clark DN, Cao F, Tavis JE, Hu J. Comparative analysis of hepatitis B virus polymerase sequences required for viral RNA binding, RNA packaging, and protein priming. Journal of Virology. 88: 1564-72. PMID 24227865 DOI: 10.1128/Jvi.02852-13  0.364
2013 Tavis JE, Gehring AJ, Hu Y. How further suppression of virus replication could improve current HBV treatment. Expert Review of Anti-Infective Therapy. 11: 755-7. PMID 23977931 DOI: 10.1586/14787210.2013.814846  0.322
2013 Hu Y, Cheng X, Cao F, Huang A, Tavis JE. β-Thujaplicinol inhibits hepatitis B virus replication by blocking the viral ribonuclease H activity. Antiviral Research. 99: 221-9. PMID 23796982 DOI: 10.1016/j.antiviral.2013.06.007  0.414
2013 Tavis JE, Cheng X, Hu Y, Totten M, Cao F, Michailidis E, Aurora R, Meyers MJ, Jacobsen EJ, Parniak MA, Sarafianos SG. The hepatitis B virus ribonuclease H is sensitive to inhibitors of the human immunodeficiency virus ribonuclease H and integrase enzymes. Plos Pathogens. 9: e1003125. PMID 23349632 DOI: 10.1371/Journal.Ppat.1003125  0.368
2013 Schvoerer E, Moenne-Loccoz R, Murray JM, Velay A, Turek M, Fofana I, Fafi-Kremer S, Erba AC, Habersetzer F, Doffoël M, Gut JP, Donlin MJ, Tavis JE, Zeisel MB, Stoll-Keller F, et al. Hepatitis C virus envelope glycoprotein signatures are associated with treatment failure and modulation of viral entry and neutralization. The Journal of Infectious Diseases. 207: 1306-15. PMID 23335805 DOI: 10.1093/Infdis/Jit032  0.501
2013 Terrault NA, Dodge JL, Murphy EL, Tavis JE, Kiss A, Levin TR, Gish RG, Busch MP, Reingold AL, Alter MJ. Sexual transmission of hepatitis C virus among monogamous heterosexual couples: the HCV partners study. Hepatology (Baltimore, Md.). 57: 881-9. PMID 23175457 DOI: 10.1002/Hep.26164  0.434
2012 Lara J, Tavis JE, Donlin MJ, Lee WM, Yuan HJ, Pearlman BL, Vaughan G, Forbi JC, Xia GL, Khudyakov YE. Coordinated evolution among hepatitis C virus genomic sites is coupled to host factors and resistance to interferon In Silico Biology. 11: 213-224. PMID 23202423 DOI: 10.3233/ISB-2012-0456  0.37
2012 George SL, Varmaz D, Tavis JE, Chowdhury A. The GB virus C (GBV-C) NS3 serine protease inhibits HIV-1 replication in a CD4+ T lymphocyte cell line without decreasing HIV receptor expression. Plos One. 7: e30653. PMID 22292009 DOI: 10.1371/Journal.Pone.0030653  0.746
2011 Tavis JE, Donlin MJ, Aurora R, Fan X, Di Bisceglie AM. Prospects for personalizing antiviral therapy for hepatitis C virus with pharmacogenetics. Genome Medicine. 3: 8. PMID 21345258 DOI: 10.1186/Gm222  0.498
2011 Wagoner J, Morishima C, Graf TN, Oberlies NH, Teissier E, Pécheur EI, Tavis JE, Polyak SJ. Differential in vitro effects of intravenous versus oral formulations of silibinin on the HCV life cycle and inflammation. Plos One. 6: e16464. PMID 21297992 DOI: 10.1371/Journal.Pone.0016464  0.477
2011 Cao F, Donlin MJ, Turner K, Cheng X, Tavis JE. Genetic and biochemical diversity in the HCV NS5B RNA polymerase in the context of interferon α plus ribavirin therapy. Journal of Viral Hepatitis. 18: 349-57. PMID 20529202 DOI: 10.1111/j.1365-2893.2010.01316.x  0.428
2011 Lara J, Tavis JE, Donlin MJ, Lee WM, Yuan HJ, Pearlman BL, Vaughan G, Forbi JC, Xia GL, Khudyakov YE. Host-specific HCV evolution and response to the combined interferon and ribavirin therapy 2011 Ieee International Conference On Bioinformatics and Biomedicine Workshops, Bibmw 2011. 102-109. DOI: 10.1109/BIBMW.2011.6112361  0.362
2010 Wagoner J, Negash A, Kane OJ, Martinez LE, Nahmias Y, Bourne N, Owen DM, Grove J, Brimacombe C, McKeating JA, Pécheur EI, Graf TN, Oberlies NH, Lohmann V, Cao F, ... Tavis JE, et al. Multiple effects of silymarin on the hepatitis C virus lifecycle. Hepatology (Baltimore, Md.). 51: 1912-21. PMID 20512985 DOI: 10.1002/Hep.23587  0.511
2010 Donlin MJ, Cannon NA, Aurora R, Li J, Wahed AS, Di Bisceglie AM, Tavis JE. Contribution of genome-wide HCV genetic differences to outcome of interferon-based therapy in Caucasian American and African American patients. Plos One. 5: e9032. PMID 20140258 DOI: 10.1371/Journal.Pone.0009032  0.778
2009 Badtke MP, Khan I, Cao F, Hu J, Tavis JE. An interdomain RNA binding site on the hepadnaviral polymerase that is essential for reverse transcription. Virology. 390: 130-8. PMID 19467554 DOI: 10.1016/J.Virol.2009.04.023  0.727
2009 Cannon NA, Donlin MJ, Mayes LM, Lyra AC, Di Bisceglie AM, Tavis JE. Evidence for action of ribavirin through the hepatitis C virus RNA polymerase Journal of Viral Hepatitis. 16: 595-604. PMID 19243495 DOI: 10.1111/J.1365-2893.2009.01109.X  0.793
2009 Dazert E, Neumann-Haefelin C, Bressanelli S, Fitzmaurice K, Kort J, Timm J, McKiernan S, Kelleher D, Gruener N, Tavis JE, Rosen HR, Shaw J, Bowness P, Blum HE, Klenerman P, et al. Loss of viral fitness and cross-recognition by CD8+ T cells limit HCV escape from a protective HLA-B27-restricted human immune response. The Journal of Clinical Investigation. 119: 376-86. PMID 19139562 DOI: 10.1172/Jci36587  0.364
2009 Aurora R, Donlin MJ, Cannon NA, Tavis JE. Genome-wide hepatitis C virus amino acid covariance networks can predict response to antiviral therapy in humans Journal of Clinical Investigation. 119: 225-236. PMID 19104147 DOI: 10.1172/Jci37085  0.794
2009 Cao F, Scougall CA, Jilbert AR, Tavis JE. Pre-P is a secreted glycoprotein encoded as an N-terminal extension of the duck hepatitis B virus polymerase gene. Journal of Virology. 83: 1368-78. PMID 19004940 DOI: 10.1128/JVI.01263-08  0.314
2008 Cannon NA, Donlin MJ, Fan X, Aurora R, Tavis JE. Hepatitis C virus diversity and evolution in the full open-reading frame during antiviral therapy. Plos One. 3: e2123. PMID 18463735 DOI: 10.1371/Journal.Pone.0002123  0.798
2007 Brodsky LI, Wahed AS, Li J, Tavis JE, Tsukahara T, Taylor MW. A novel unsupervised method to identify genes important in the anti-viral response: application to interferon/ribavirin in hepatitis C patients. Plos One. 2: e584. PMID 17589564 DOI: 10.1371/Journal.Pone.0000584  0.412
2007 Donlin MJ, Cannon NA, Yao E, Li J, Wahed A, Taylor MW, Belle SH, Di Bisceglie AM, Aurora R, Tavis JE. Pretreatment sequence diversity differences in the full-length hepatitis C virus open reading frame correlate with early response to therapy. Journal of Virology. 81: 8211-24. PMID 17522222 DOI: 10.1128/Jvi.00487-07  0.791
2007 Taylor MW, Tsukahara T, Brodsky L, Schaley J, Sanda C, Stephens MJ, McClintick JN, Edenberg HJ, Li L, Tavis JE, Howell C, Belle SH. Changes in gene expression during pegylated interferon and ribavirin therapy of chronic hepatitis C virus distinguish responders from nonresponders to antiviral therapy. Journal of Virology. 81: 3391-401. PMID 17267482 DOI: 10.1128/Jvi.02640-06  0.434
2007 Zhou D, Fan X, Tan D, Xu Y, Tavis JE, Di Bisceglie AM. Separation of near full-length hepatitis C virus quasispecies variants from a complex population. Journal of Virological Methods. 141: 220-4. PMID 17208310 DOI: 10.1016/j.jviromet.2006.12.002  0.397
2006 Badtke MP, Cao F, Tavis JE. Combining genetic and biochemical approaches to identify functional molecular contact points. Biological Procedures Online. 8: 77-86. PMID 17033698 DOI: 10.1251/Bpo121  0.716
2006 Cao F, Tavis JE. Suppression of mRNA accumulation by the duck hepatitis B virus reverse transcriptase. Virology. 350: 475-83. PMID 16563457 DOI: 10.1016/j.virol.2006.02.026  0.39
2005 Yao E, Tavis JE. A general method for nested RT-PCR amplification and sequencing the complete HCV genotype 1 open reading frame. Virology Journal. 2: 88. PMID 16321149 DOI: 10.1186/1743-422X-2-88  0.473
2005 Cao F, Badtke MP, Metzger LM, Yao E, Adeyemo B, Gong Y, Tavis JE. Identification of an essential molecular contact point on the duck hepatitis B virus reverse transcriptase. Journal of Virology. 79: 10164-70. PMID 16051809 DOI: 10.1128/Jvi.79.16.10164-10170.2005  0.73
2005 Tester I, Smyk-Pearson S, Wang P, Wertheimer A, Yao E, Lewinsohn DM, Tavis JE, Rosen HR. Immune evasion versus recovery after acute hepatitis C virus infection from a shared source. The Journal of Experimental Medicine. 201: 1725-31. PMID 15939788 DOI: 10.1084/Jem.20042284  0.464
2004 Cao F, Tavis JE. Detection and characterization of cytoplasmic hepatitis B virus reverse transcriptase Journal of General Virology. 85: 3353-3360. PMID 15483251 DOI: 10.1099/vir.0.80297-0  0.392
2004 Yao E, Tavis JE. Localization of duck hepatitis B virus polymerase within cells. Methods in Molecular Medicine. 95: 281-93. PMID 14762311 DOI: 10.1385/1-59259-669-X:281  0.349
2003 Yao E, Schaller H, Tavis JE. The duck hepatitis B virus polymerase and core proteins accumulate in different patterns from their common mRNA. Virology. 311: 81-8. PMID 12832205 DOI: 10.1016/S0042-6822(03)00142-9  0.306
2003 Yao E, Tavis JE. Kinetics of synthesis and turnover of the duck hepatitis B virus reverse transcriptase. The Journal of Biological Chemistry. 278: 1201-5. PMID 12444091 DOI: 10.1074/jbc.M208895200  0.331
2001 Gong Y, Yao E, Tavis JE. Evidence that the RNAseH activity of the duck hepatitis B virus is unable to act on exogenous substrates. Bmc Microbiology. 1: 12. PMID 11504562 DOI: 10.1186/1471-2180-1-12  0.378
2000 Yao E, Gong Y, Chen N, Tavis JE. The majority of duck hepatitis B virus reverse transcriptase in cells is nonencapsidated and is bound to a cytoplasmic structure. Journal of Virology. 74: 8648-57. PMID 10954566 DOI: 10.1128/JVI.74.18.8648-8657.2000  0.383
1998 Tavis JE, Massey B, Gong Y. The duck hepatitis B virus polymerase is activated by its RNA packaging signal, epsilon. Journal of Virology. 72: 5789-96. PMID 9621038 DOI: 10.1128/JVI.72.7.5789-5796.1998  0.357
1993 Tavis JE, Ganem D. Expression of functional hepatitis B virus polymerase in yeast reveals it to be the sole viral protein required for correct initiation of reverse transcription Proceedings of the National Academy of Sciences of the United States of America. 90: 4107-4111. PMID 7683422 DOI: 10.1073/Pnas.90.9.4107  0.35
1989 Tavis JE, Walker DL, Gardner SD, Frisque RJ. Nucleotide sequence of the human polyomavirus AS virus, an antigenic variant of BK virus Journal of Virology. 63: 901-911. PMID 2536111 DOI: 10.1128/Jvi.63.2.901-911.1989  0.324
Show low-probability matches.